Novel inhibitors of checkpoint kinase 1. (Q36939959)

17 August 2017

1 reference

title

Novel inhibitors of checkpoint kinase 1. (English)

1 reference

17 August 2017

Kenneth L Arrington

1 reference

17 August 2017

Vadim Y Dudkin

series ordinal

1 reference

17 August 2017

publication date

1 November 2007

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

page(s)

1571-1585

1 reference

Novel checkpoint 1 inhibitors

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

Virtual screening and fast automated docking methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

Sleeping policemen for DNA replication?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

ATR and ATM regulate the timing of DNA replication origin firing

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Cell-cycle checkpoints and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Targeting the checkpoint kinases: chemosensitization versus chemoprotection

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic cata

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

DNA damage-induced mitotic catastrophe is mediated by the Chk1-dependent mitotic exit DNA damage checkpoint

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Kinesin spindle protein (KSP) inhibitors. Part 2: the design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas [correction of cyanopyrazi] as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Chk1 inhibitors for novel cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Cdc25 phosphatases and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors: effects of 5-amido- and 5-sulphonamido-indolyl groups on pharmacokinetics and hERG binding

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

The role of Cdk7 in CAK function, a retro-retrospective

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Identification of chemically diverse Chk1 inhibitors by receptor-based virtual screening.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Structure-based design of novel Chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

High-throughput docking for lead generation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Docking and scoring in virtual screening for drug discovery: methods and applications

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Cdc2 tyrosine phosphorylation is required for the DNA damage checkpoint in fission yeast

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Structure-activity relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione Inhibitors of the Checkpoint Kinase Wee1. Structure−Activity Relationships for Chromophore Modification and Phenyl Ring Substitution

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Structural basis for Chk1 inhibition by UCN-01

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

4-(Aminoalkylamino)-3-benzimidazole-quinolinones as potent CHK-1 inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Pyrazolo[5,1-b]quinazolin-9-ones: a new series of antiallergic agents

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Development of 6-substituted indolylquinolinones as potent Chek1 kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Cell permeability as a parameter for lead generation in the protein Tyrosine kinase inhibition field

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Oncogenic kinase signalling

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Biology of the p21-activated kinases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Signaling intricacies take center stage in cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700131

7 January 2021

Identifiers

DOI

10.1002/CMDC.200700131

1 reference

17 August 2017

1 reference